Biovail, J&J, Par Pharmaceutical, Purdue Pharma neurology news

The U.S. Court of Appeals for the Federal Circuit upheld a lower court's decision last year that two of Purdue's patents covering Ultram ER tramadol extended-release tablets were invalid due to obviousness. The decision allows Par to market its generic upon final FDA approval. ...